For a significant number of people with high blood pressure medication is not effective in controlling their condition. For them, new therapies are being explored that control hypertension by disconnecting the nerve along the renal artery that has been found to contribute to the condition.
Ablative Solutions Inc. of Kalamazoo is one of the companies pursuing a course of treatment that addresses hypertension and other diseases related to overactive sympathetic nerve activity. The company recently announced its work has received $5.3 million in first round financing. BioStar Ventures and the Michigan Accelerator Fund were among the multiple angel investors who backed the project.
The Company projects that its clinical evaluations will begin in 2013. Ablative Solutions Inc. was founded by experienced medical device entrepreneurs Tim Fischell, MD, and David Fischell, PhD.
The sympathetic nerves that run along the renal artery play an essential role in controlling blood pressure. When overactive they contribute to hypertension. Interrupting the message from those nerves has reduced blood pressure in patients who are not effectively treated by other medical therapies. Ablative Solutions' therapy is designed to simplify and streamline the procedure and do so without damaging the vessel wall by delivering the therapy directly to where the sympathetic nerves reside, just outside the blood vessel.
"Our technology development is driven by the awareness that less is more -- providing optimized ablation of the sympathetic nerve less invasively and with less equipment and a shorter procedure time," says Dr. Vartan Ghazarossian, President and COO of Ablative Solutions Inc.
Writer: Kathy Jennings, Second Wave Media
Source: Vartan Ghazarossian, Ablative Solutions Inc.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.